High-dose immunoglobulin infusion for thrombotic thrombocytopenic purpura refractory to plasma exchange and steroid therapy.
The outcomes of the treatment of thrombotic thrombocytopenic purpura (TTP) have been shown to be improved by the administration of plasma exchange. However, treatment options are currently limited for cases refractory to plasma exchange. The autoantibodies that block the activity of ADAMTS13 have been demonstrated to play a role in the pathogenesis of TTP; therefore, high-dose immunoglobulin, which can neutralize these autoantibodies, may be useful for refractory TTP. However, successful treatment with high-dose immunoglobulin for TTP refractory to plasma exchange and corticosteroids has yet to be reported in Korea. Herein, we describe a refractory case which was treated successfully with high-dose immunoglobulin. A 29-year-old male diagnosed with TTP failed to improve after plasma exchange coupled with additional high-dose corticosteroid therapy. As a salvage treatment, we initiated a 7-day regimen of high-dose immunoglobulin (400 mg/kg) infusions, which resulted in a complete remission, lasting up to the last follow-up at 18 months. High-dose immunoglobulin may prove to be a useful treatment for patients refractory to plasma exchange; it may also facilitate recovery and reduce the need for plasma exchange.
Park
Seh Jong
SJ
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Kim
Seok Jin
SJ
Seo
Hee Yun
HY
Jang
Moon Ju
MJ
Oh
Doyeun
D
Kim
Byung Soo
BS
Kim
Jun Suk
JS
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010951:Plasma Exchange; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy*; D016879:Salvage Therapy; D055502:Secondary Prevention; D017211:Treatment Failure
D000305:Adrenal Cortex Hormones; D007136:Immunoglobulins
Br J Haematol. 2000 Mar;108(4):880-2
10792300
Haematologica. 1995 Jul-Aug;80(4):325-31
7590501
Acta Haematol. 1996;96(4):255-7
8922496
Blood. 1996 May 15;87(10):4235-44
8639782
Transfusion. 2001 Jun;41(6):840-4
11399830
N Engl J Med. 1998 Nov 26;339(22):1585-94
9828246
J Clin Apher. 1998;13(3):120-5
9828022
Am J Hematol. 2000 Nov;65(3):251-5
11074544
Am J Hematol. 2004 Oct;77(2):171-6
15389904
J Clin Invest. 1984 Feb;73(2):548-55
6538207
Br J Haematol. 1996 Aug;94(2):383-6
8759902
Acta Haematol. 2001;105(4):204-8
11528094
Am J Hematol. 1995 Oct;50(2):84-90
7573005
Blood. 2000 Aug 15;96(4):1223-9
10942361
N Engl J Med. 1991 Aug 8;325(6):393-7
2062330
N Engl J Med. 2002 Aug 22;347(8):589-600
12192020
N Engl J Med. 1998 Nov 26;339(22):1578-84
9828245
Kidney Int. 2001 Sep;60(3):831-46
11532079
Blood. 1996 May 15;87(10):4223-34
8639781
J Clin Apher. 2001;16(1):19-22
11309826
Am J Clin Pathol. 2006 Apr;125(4):592-7
16627268